ALK and neoplasm: Furthermore it must be considered that none of the available FISH assays, except the one of Zytovision, delivers any information about the fusion partner in ALK rearrangement [64,78,79,80,81,82] and that, up to now, there is no information available if all variants of ALK fusions respond to the TKI therapy in the same way, leading to the conclusion that the therapy success of Crizotinib could depend on the ALK variant present in the respective tumor.